Published in J Steroid Biochem Mol Biol on February 24, 2005
Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer (2009) 1.32
The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers. Br J Cancer (2007) 0.91
BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure. Br J Cancer (2009) 0.89
Steroidomimetic Tetrahydroisoquinolines for the Design of New Microtubule Disruptors. ACS Med Chem Lett (2011) 0.87
Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study. Biol Res (2014) 0.78
The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression. Anticancer Res (2015) 0.75
Induction of the intrinsic apoptotic pathway via a new antimitotic agent in an esophageal carcinoma cell line. Cell Biosci (2014) 0.75
Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J Biol Chem (2007) 2.20
Identification of mammalian Vps24p as an effector of phosphatidylinositol 3,5-bisphosphate-dependent endosome compartmentalization. J Biol Chem (2003) 1.76
Regulation of Ins(3,4,5,6)P(4) signaling by a reversible kinase/phosphatase. Curr Biol (2002) 1.69
Determination of neo- and D-chiro-inositol hexakisphosphate in soils by solution 31P NMR spectroscopy. Environ Sci Technol (2012) 1.53
The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res (2002) 1.51
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res (2005) 1.38
NAADP-mediated Ca2+ signaling via type 1 ryanodine receptor in T cells revealed by a synthetic NAADP antagonist. Proc Natl Acad Sci U S A (2009) 1.30
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene (2004) 1.28
2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem (2006) 1.25
RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo. J Biol Chem (2005) 1.17
Synthetic partial agonists reveal key steps in IP3 receptor activation. Nat Chem Biol (2009) 1.12
Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. Int J Cancer (2004) 1.11
Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerization, secondary mediators, and Rac. Blood (2010) 1.11
Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res (2006) 1.10
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer (2008) 1.10
Novel non-steroidal inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. J Steroid Biochem Mol Biol (2007) 1.10
Novel 18beta-glycyrrhetinic acid analogues as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenases. Bioorg Med Chem (2004) 1.10
The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res (2006) 1.09
Regulation of estrogen synthesis in postmenopausal women. Steroids (2002) 1.07
3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity. J Med Chem (2007) 1.04
STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clin Cancer Res (2008) 1.02
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents. J Med Chem (2005) 1.02
Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function. PLoS One (2011) 1.02
Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer (2008) 1.00
Rapid functional assays of recombinant IP3 receptors. Cell Calcium (2005) 0.99
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate. J Med Chem (2010) 0.99
Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. J Steroid Biochem Mol Biol (2003) 0.98
Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. Brain (2010) 0.98
2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res Treat (2007) 0.98
Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol (2005) 0.98
Rap1-Rac1 circuits potentiate platelet activation. Arterioscler Thromb Vasc Biol (2011) 0.97
Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono- and bis-3-O-sulphamates. Int J Cancer (2005) 0.97
Catalysis-associated conformational changes revealed by human CD38 complexed with a non-hydrolyzable substrate analog. J Biol Chem (2007) 0.95
Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist (2007) 0.94
Regulation of casein kinase-2 (CK2) activity by inositol phosphates. J Biol Chem (2004) 0.94
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. J Med Chem (2008) 0.94
Rapid synthetic route toward structurally modified derivatives of cyclic adenosine 5'-diphosphate ribose. J Org Chem (2005) 0.93
scyllo-inositol pentakisphosphate as an analogue of myo-inositol 1,3,4,5,6-pentakisphosphate: chemical synthesis, physicochemistry and biological applications. Chembiochem (2006) 0.93
Adenophostin A and analogues modified at the adenine moiety: synthesis, conformational analysis and biological activity. Org Biomol Chem (2004) 0.93
Synthesis of stable and cell-type selective analogues of cyclic ADP-ribose, a Ca(2+)-mobilizing second messenger. Structure--activity relationship of the N1-ribose moiety. J Am Chem Soc (2005) 0.93
Biphenyl 2,3',4,5',6-pentakisphosphate, a novel inositol polyphosphate surrogate, modulates Ca2+ responses in rat hepatocytes. FASEB J (2007) 0.93
The enzymes of human diphosphoinositol polyphosphate metabolism. FEBS J (2013) 0.92
Regioselective hydrolysis of myo-inositol 1,3,5-orthobenzoate via a 1,2-bridged 2'-phenyl-1',3'-dioxolan-2'-ylium ion provides a rapid route to the anticancer agent Ins(1,3,4,5,6)P5. Chem Commun (Camb) (2006) 0.92
First synthetic analogues of diphosphoinositol polyphosphates: interaction with PP-InsP5 kinase. Chem Commun (Camb) (2012) 0.92
Binding of inositol 1,4,5-trisphosphate (IP3) and adenophostin A to the N-terminal region of the IP3 receptor: thermodynamic analysis using fluorescence polarization with a novel IP3 receptor ligand. Mol Pharmacol (2010) 0.92
Synthesis and Ca2+-mobilizing activity of purine-modified mimics of adenophostin A: a model for the adenophostin-Ins(1,4,5)P3 receptor interaction. J Med Chem (2003) 0.92
Interactions of inositol 1,4,5-trisphosphate (IP(3)) receptors with synthetic poly(ethylene glycol)-linked dimers of IP(3) suggest close spacing of the IP(3)-binding sites. J Biol Chem (2002) 0.92
Chimeric microtubule disruptors. Chem Commun (Camb) (2010) 0.92
Novel hydrolysis-resistant analogues of cyclic ADP-ribose: modification of the "northern" ribose and calcium release activity. Biochemistry (2002) 0.91
Structural basis for enzymatic evolution from a dedicated ADP-ribosyl cyclase to a multifunctional NAD hydrolase. J Biol Chem (2009) 0.91
A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anticancer Res (2008) 0.90